Merck names Cressey managing partner Paul Diaz to board effective Nov. 1, 2026
Merck appointed Paul J. Diaz, managing partner at Cressey & Company, to its board effective Nov. 1, 2026. Diaz previously served as CEO of Myriad Genetics, leading genetic testing and precision medicine, earlier running Kindred Healthcare. Board size will increase to 14 directors; Diaz is set to stand for election at t